The table below shows RAPT Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
Operating cash flow
-$83.30M
-$97.05M
-$70.77M
-$61.03M
-$40.49M
-$35.47M
Capital expenditure
$122.00K
$1.13M
$845.00K
$755.00K
$398.00K
$888.00K
Investing cash flow
$52.70M
$104.13M
-$45.49M
-$81.35M
-$87.44M
-$843.00K
Dividends paid
-
-
-
-
RAPT operating cash flow (10-K history)
RAPT Therapeutics, Inc. reported operating cash flow of -$83.30M for fiscal year 2024. That is up 14.2% from -$97.05M in fiscal 2023. Over the 7 fiscal years shown, operating cash flow declined from -$32.95M (FY 2018) to -$83.30M. Figures come from the company's audited annual reports as filed with the SEC.